Intensive chemotherapy in aggressive lymphomas: updated results of LNH-80 protocol and prognostic factors affecting response and survival.

Abstract

One hundred patients with aggressive malignant lymphomas treated with the LNH-80 regimen were evaluated for long-term survival and pretreatment characteristics predictive of response and survival. LNH-80 consists of three intensive courses of adriamycin cyclophosphamide vindesine bleomycin (ACVB) followed by sequential consolidation and final intensification. Eighty-four patients went into complete remission (CR), eight had a partial response (PR), three failed to respond, and five died during induction. Twenty-three patients (27%) relapsed, in two of whom a prolonged second remission was obtained. Sixty-three patients are currently alive, two of them with disease. Four patients died in CR. Median survival and median freedom from relapse survival were not reached with a median follow-up of 4 1/2 years. Characteristics negatively associated with response in multivariate analysis were: poor performance status, bone marrow involvement, and two or more extranodal sites of disease. Duration of CR was associated with splenic involvement. Three characteristics were negatively associated with survival in multivariate analysis: age, high grade subtypes, and bone marrow involvement.

• Authors: B Coiffier, P A Bryon, M Ffrench, M Blanc, C Sebban, F Berger, J J Viala
• Journal: Blood (Blood) Vol. 70 Issue 5 Pg. 1394-9 (Nov 1987) ISSN: 0006-4971 [Print] United States
• PMID: 2444287 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Bleomycin
• Vincristine
• Doxorubicin
• Cyclophosphamide

Topics

• Antineoplastic Combined Chemotherapy Protocols
• Bleomycin (therapeutic use)
• Cyclophosphamide (therapeutic use)
• Doxorubicin (therapeutic use)
• Drug Administration Schedule
• Follow-Up Studies
• Humans
• Lymphoma (drug therapy, mortality)
• Middle Aged
• Prognosis
• Vincristine (therapeutic use)